

All.Can editorial control policy

Consensus and editorial control

- All.Can is led by its members.
- As outlined in our [Terms of Reference](#), members are responsible for all decisions relating to the scope of activities and have full editorial control over the content of all outputs, with all members having an equal say.
- All programmes of work aim to accurately represent a consensus between members.
- All member contributions to materials are welcomed and equally valid/valued – irrespective of membership status. No one constituency, e.g. patient advocacy or industry, has editorial control.
- Funding partners do not receive preferential of ‘special’ status and therefore cannot influence outputs or content of materials more than any other member.

Approval process

- Members of the different working groups, as relevant to each given output, are asked to offer comments and proposed edits on reports, publications and communications materials.
- The secretariat is responsible for providing iterative drafts of any documents to working group members, collating comments, correcting any factual inaccuracies and leading the drafting process in close consultation with all relevant members.
- Comments are requested within a designated timeframe and must be provided within this timeframe to be considered.
- Any major differences of opinion between members will be taken on board by the secretariat. This is to ensure that no single member can take editorial control. Any major discrepancies will be submitted to the Steering Committee for ultimate sign-off.
- All member quotes included within any All.Can materials will be approved in writing by the individual cited using the appropriate copy clearance forms.
- To ensure adherence to industry standards, each funding partner must submit all major outputs (e.g. policy reports) which All.Can has produced, to an internal legal and compliance review. The comments received from this review will be considered alongside the comments received from all other members for all materials produced by the programme.
- Once approved, and prior to publication or external dissemination, approved materials are sent to the wider membership for information. Any factual inaccuracies at this point will be rectified.

All.Can is a multi-stakeholder platform established to create political and public engagement on the need to improve the efficiency in cancer care. To do this, it focuses on what matters most to patients, and makes sure resources are targeted towards achieving these outcomes. All members contribute their time for free to the initiative, and all publications from the group reflect consensus of the members, who hold full editorial control. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors). The secretariat to All.Can is provided by The Health Policy Partnership Ltd.

© 2018 The Health Policy Partnership. All rights reserved.

Date of preparation: April 2018

All.Can editorial control policy

Accuracy and quality of information

- All.Can and its membership are committed to providing accurate, impartial and balanced information.
- The secretariat ensures that All.Can outputs are scrutinised and adhere to highest quality standards, comply with copyright law and reflect the most up-to-date medical evidence available.
- The secretariat will keep accurate records for version control of materials and make amendments to copy by way of tracked changes.

Transparency

- All.Can was established for research and education purposes only. As a result, its outputs are all strictly non-promotional and never promote or endorse any specific treatments or medicines.
- In the interests of transparency, all members must complete a declaration of interests as part of their membership application form.
- All funding sources for All.Can are transparently reported on all publications and outputs.

Media policy

- International proactive and reactive media statements will be drafted by the All.Can secretariat and approved by the Communications, events and stakeholder engagement working group, with final sign-off by the Steering Committee as with other All.Can materials.
- The secretariat has been bestowed the trust and authority of the Steering Committee to act as All.Can's official spokesperson (where no working group member or Steering Committee member is available for media comment).
- Verbal comment or statements can be issued by the secretariat on All.Can's behalf where existing, approved key messages and proactive media statements have been approved by the working groups and Steering Committee. Approval of media materials follows the same approval process as outlined as above.
- However, it should be noted that reactive media statements, which require speedy and immediate turnaround, will not be copied to the wider group prior to publication but circulated to the group for information as soon as practicably possible.

All.Can is a multi-stakeholder platform established to create political and public engagement on the need to improve the efficiency in cancer care. To do this, it focuses on what matters most to patients, and makes sure resources are targeted towards achieving these outcomes. All members contribute their time for free to the initiative, and all publications from the group reflect consensus of the members, who hold full editorial control. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD and Johnson & Johnson (sponsors). The secretariat to All.Can is provided by The Health Policy Partnership Ltd.

© 2018 The Health Policy Partnership. All rights reserved.

Date of preparation: April 2018